



Overview about Oxidative stress in Toxoplasmosis

Nagwa Ibrahim Hassan Ibrahim *, Soad Mahdy Morsy Nada, Marwa Ahmed Mohammed Salama, Eman Mostafa Abd El-Rahman

Medical Parasitology Department, Faculty of Medicine, Zagazig University, Egypt

Email: mohnagwa2020@gmail.com, nagwai@medicine.zu.edu.eg

Article History: Received: 01.03.2023

Revised:07.03.2023

Accepted: 11.03.2023

Abstract

The protozoan parasite was named *Toxoplasma gondii* based on its morphology: “toxo” for arc- form; “plasma” for life and “gondii” for the host where it was first found. Although a single species has been described for the genus *Toxoplasma*, there are several clonal lineages that differ in their pathogenicity and virulence. The primary mechanism of the host's defence against protozoan infection is oxidative stress (OS). Oxidative stress is defined as an imbalance between the production of reactive oxygen species (ROS) and the antioxidant system of the organism. ROS include all highly reactive and unstable derivatives of molecular oxygen, such as hydrogen peroxide (H₂O₂), superoxide anion (-O₂) and the most dangerous hydroxyl radical (HO). The characteristic action of ROS is the degradation of polyunsaturated fatty acids in the process termed lipid peroxidation, which leads to the production of harmful molecules, including malondialdehyde (MDA). *T. gondii* is one of many intracellular infections that can be killed by ROS which are produced during an immune response. It was discovered that ROS can stop *T. gondii* from growing in infected animals' monocytes. For instance, high H₂O₂ concentrations may prevent tachyzoites from proliferating intracellularly. Superoxide dismutases (SODs) (one cytosolic and two mitochondrial), catalase (CAT), and three peroxiredoxins, including one 1-Cys peroxiredoxin and two 2-Cys peroxiredoxins, are all expressed by toxoplasma cells.

Keywords: Oxidative stress, Toxoplasmosis

DOI: : 10.31838/ecb/2023.12.1.024

Introduction

Toxoplasma gondii was discovered by both **Nicolle** and **Manceaux** in 1908 in the lymphatics and liver of *Ctenodactylus gondii* (the North African rodent) and in rabbits in Brazil (**Ferguson, 2009**). The protozoan parasite was named *Toxoplasma gondii* based on its morphology: “toxo” for arc- form; “plasma” for life and “gondii” for the host where it was first found (**Weiss and Dubey, 2009**).

The parasite is infecting broad range of warm- blooded animals including one third of world human population (**Montoya and Liesenfeld,2004**). The pathogenic potential of *Toxoplasma gondii* was recognized in 1920s and 1930s (**Weiss and Dubey, 2009**).

T. gondii is a globally distributed protozoan parasite which can infect about 30 to 50% of human populations. In Europe more than one million of the reported annual cases are contracting infection through drinking oocyst-contaminated water or ingestion of tissue cyst-contaminated food, primarily raw or undercooked pork and lamb (**WHO, 2015**).

Prevalence in USA and United Kingdom ranges from 8 to 22% (**Jones et al, 2014**). In USA, toxoplasmosis was the fourth cause of hospitalization after salmonellosis, campylobacteriosis and Norovirus infections (**Scallan et al, 2011**).

In Central America, South America, and continental Europe, estimates of infection range from 30 to 90% (**Minbaeva et al., 2013**). In both developing and developed countries, the parasite infects approximately 30-50% of the human population (**Flegr et al., 2014**).

The highest seroprevalence of *T. gondii* has been reported from developing countries like Ethiopia. For example, the seroprevalence of *T. gondii* recorded in northern Ethiopia was 76.5% (**Muluye et al., 2013**).

The consumption of contaminated food is the main source of infection, including meat products and dairy products. Recently, contamination has been detected in fresh products with oocysts and marine products. Despite the great health problems that are caused by *T. gondii*, currently there are no standardized methods for its detection in the food industry (**Marín-García et al., 2022**).

Although, contaminated food is considered the main route of infection in humans, it has been reported that up to 50% of infections are caused by food transmission using a novel multiplex Polymerase Chain reaction (PCR) assay (**Shapiro et al., 2019**). **Luna et al., 2019**, informed the presence of *T. gondii* in meat, water, cucumber, and guava juice, both inert and living surfaces in school dining rooms of Colombia.

The concern about this zoonosis and its transmission has been increasing. In 2018, the EFSA recommended a serological screening of livestock to identify positive farms (**Shapiro et al., 2019**). In the following year, The European Food Safety Authority (EFSA) report found that food-borne transmission accounts for 40–60% of *T. gondii* infections (**EFSA and ECDC, 2019**).

Reports from Iran showed that chronic toxoplasmosis was a risk factor for type 2 diabetes mellitus (**Colli et al., 2010**), however, there was no statistical relationship between serum levels of anti-*T. gondii* antibodies and the risk for diabetes mellitus (**Khalili et al., 2018**). In fact, the reason for high seroprevalence of *T. gondii* infection among diabetic patients and the mechanism by which toxoplasmosis relates to diabetes mellitus are not clearly defined (**Woyesa and Taylor-Robinson, 2021**).

On the other hand, there is a variation in seroprevalence between domestic animals and human. In a study conducted in China from 2000 to 2017, toxoplasmic infection was about four times more likely to occur in domestic animals than in humans (23.4% versus 8.2%) (**Dong et al., 2018**). A similar study conducted in seven Chinese regions reported high seroprevalence of *T. gondii* among meat-producing animals, with pigs, chickens and cattle having a 24, 20 and 9.5% rate of infection, respectively (**Deng et al., 2018**). Also, it was found that frequent contact with domestic cats was independent predictor to acquire *T. gondii* infection (**Wilking et al., 2016**).

Hamed et al. (2018) detected a significant seroprevalence of toxoplasmosis in mentally retarded children attending Abu Reesh Hospital of Cairo University. Therefore, screening for toxoplasmosis during pregnancy is important especially when mothers are exposed to risk factors such as contact with cats and consumption of undercooked meat.

Furthermore, the same researchers conducted a study to evaluate the seroprevalence of *T. gondii* infection in diabetic patients. They found that the seropositivity for anti-*Toxoplasma* antibodies in diabetic patients was found to be higher than that in non-diabetic patients.

Interestingly, the seroprevalence of *T. gondii* of cats was reported to be 97% in Egypt (**Al-Kappany et al., 2011**). Moreover, **Khatab et al., 2019** revealed a seroprevalence of 45.0 and 5.0% in type 1 diabetic patients by anti-IgG and anti-IgM.

Oxidative stress in Toxoplasmosis:

The primary mechanism of the host's defence against protozoan infection is oxidative stress (OS) (**Delavari et al., 2017**). Oxidative stress is defined as an imbalance between the production of reactive oxygen species (ROS) and the antioxidant system of the organism (**Betteridge, 2000**).

ROS include all highly reactive and unstable derivatives of molecular oxygen, such as hydrogen peroxide (H₂O₂), superoxide anion (-O₂) and the most dangerous hydroxyl radical (HO) (**Halliwell, 2012**).

ROS homeostasis is closely related to many other reactive molecules, such as reactive carbonyl species (RCS) and reactive nitrogen species (RNS) (**Lushchak, 2014**).

Since ROS are produced as a consequence of oxygen metabolism, it is impossible to avoid them in aerobic organisms. They are generated in the cytosol and in such organelles, such as mitochondria and peroxisomes (**Szewczyk-Gole et al., 2021**).

ROS play a role in cell signalling activities at physiological levels, but increased oxidative stress brought on by excessive ROS production may damage all cellular macromolecules, including lipids, proteins, and nucleic acids, ultimately resulting in cell death (**Dincel and Atmaca, 2016**).

The characteristic action of ROS is the degradation of polyunsaturated fatty acids in the process termed lipid peroxidation, which leads to the production of harmful molecules, including malondialdehyde (MDA) (**Del Rio et al., 2005**).

MDA is a highly reactive aldehyde that harms tissues by oxidation. MDA is a significant thiobarbituric acid reactive compound (TBARS) in the organism and is a member of the TBARS class. Therefore, the TBARS measurement is frequently employed to determine the MDA concentration (**Dalle-Donne et al., 2006**).

TBARS and MDA are considered the significant indicators of oxidative stress and lipid peroxidation in biological samples (**Rahal et al., 2014**).

Oxidative stress plays a significant role during *Toxoplasma* infection in the host and the parasite (**Van De Crommenacker et al., 2011**).

Cellular disruption and cell death occur as a consequence of *T. gondii*'s asexual reproduction in an infected host. Lymphocytes and other inflammatory host cells are drawn to the necrosis that results. Huge levels of ROS and RNS are produced during the immune response against the parasite (**Çinar, 2015**).

Oxidative stress resulting from the host response is toxic to parasites (**Zhuang et al., 2020**). Moreover, it is crucial in the development of toxoplasmosis in both animals and humans (**Karaman et al., 2008**).

Antioxidant Defense of *Toxoplasma gondii*:

T. gondii is one of many intracellular infections that can be killed by ROS which are produced during an immune response. It was discovered that ROS can stop *T. gondii* from growing in infected animals' monocytes. For instance, high H₂O₂ concentrations may prevent tachyzoites from proliferating intracellularly (**Xue et al., 2017**). Consequently, the parasite needs to defend itself from the host's forced oxidative burst (**Charvat and Arrizabalaga, 2016**). Superoxide dismutases (SODs) (one cytosolic and two mitochondrial), catalase (CAT), and three peroxiredoxins, including one 1-Cys peroxiredoxin and two 2-Cys peroxiredoxins, are all

expressed by toxoplasma cells (**Akerman and Müller, 2005**).

The main antioxidants involved in the protection against oxidative stress and oxidative metabolic byproducts include SODs and CAT (**Ding et al.,2000**) SODs are metalloproteins that help break down superoxide anions into molecules of oxygen and peroxide (**Scandalios, 1993**).

Hydrogen peroxide is converted by CAT to water and oxygen, which lowers its cellular level (**Charvat and Arrizabalaga, 2016**). CAT's cytosolic location and inherent kinetic characteristics imply that this enzyme may be best adapted for the defence against oxidative stress in host cells (**kwok et al.,2003**). CAT appears to have a significant role in invasion and replication inside the parasitophorous vacuoles, according to knockout studies (**Bosch et al.,2015**). *T. gondii* without CAT showed decreased virulence in mice and greater vulnerability to exogenous hydrogen peroxide (**kwok et al.,2003**).

Oxidative Stress in the Early Stages of the Acute Phase of Toxoplasmosis:

During the acute phase of toxoplasmosis, ROS are extensively produced, and oxidative stress is created in the tissues of infected animals. As the host's defense against the infection even in the absence of symptoms, *T. gondii* seropositive cats exhibit elevated ROS levels (**Faria et al.,2018**). Phagocytosis is a common component of the host immune response to infections, which occurs after lymphokines have activated mononuclear phagocytes (**Dahlgren and Karlsson, 1999**).

Although practically all mammalian tissues contain the NADPH-oxidase complex (Nox), which generates ROS, phagocytes have a more prominent role in the production of ROS in the host's defence against infections (**Bedard and Krause, 2007**). As a result, host phagocytes are the primary site where parasiticidal processes are activated via ROS production. As a factor controlling the intracellular survival of *T. gondii* parasites within macrophages, Nox-mediated ROS production (**Matta et al.,2018**).

Additionally, nitric oxide (NO) produced by macrophages was found to have an antiparasitic effect on protozoa (**Szewczyk-Gole et al.,2021**). According to **Tonin et al. (2015)**, an increase in NO levels was found in goats with toxoplasmosis. *T. gondii* infection is linked to an elevated NO level, which is produced to manage the infection. Tachyzoites of both virulent and non-virulent strains can be directly killed by NO or stimulated to produce the heat-shock protein 70, which aids in their transition to the bradyzoite stage and cyst formation (**Szewczyk-Gole et al.,2021**).

Oxidative Stress in the Later Stages of the Acute Phase of Toxoplasmosis:

The oxidant–antioxidant balance in the later stages of the acute phase of *T. gondii* infection showed increased SOD and glutathione S-transferase (GST) activities 30 days after infection in the brain, liver and kidney of rats. This suggests that the increased antioxidant defense persisting later on in the acute phase can be used to diagnose *T. gondii* infection and may be helpful, especially in cases where the diagnosis of *T. gondii* infection is difficult in the earlier stage of the acute phase (**Türko ̇glu et al., 2018**).

Oxidative damage in the host during Toxoplasma infection:

In addition to being effective against *T. gondii*, the rapid release of ROS and NO also adds to oxidative stress, which causes tissue damage and the pathophysiology of the disease (**Alajmi et al.,2019**). Damage to the intracellular lysosomal membrane caused by oxidative stress is followed by apoptosis or necrosis (**Terman et al.,2006**).

Increased lipid peroxidation is linked to decreased function of the defence system preventing tissue damage from free radicals in *Toxoplasma* seropositive people and animals (**Al-Azzaui, 2011**). It was reported that gerbils infected with *T. gondii* exhibit increased lipid peroxidation (**Szewczyk-Gole et al.,2021**). In addition, **Delavari et al. (2017)** found that rats infected with *T.*

gondii had higher levels of MDA in their liver cells, blood serum, and testes (Nazarlu *et al.*, 2020).

Humans with chronic toxoplasmosis have significantly higher MDA concentrations in their serum, according to some studies (Szewczyk-Gole *et al.*, 2021). When compared to healthy persons, the MDA levels in *Toxoplasma* seropositive patients who were asymptomatic were considerably greater (Al-Kuraishy *et al.*, 2020). There was no relationship between the MDA concentration and either gender or age (Al-Azzaury, 2011).

The antioxidant compounds

1-Resveratrol:

Resveratrol (trans-3,4',5-trihydroxystilbene, RSV), is a small polyphenol found in many plants, especially mulberries, peanuts, and grapes (Kulkarni and Canto, 2015).

RSV has a wide range of pharmacological activities, including anti-cancer (Ko *et al.*, 2017), anti-oxidant (Xia *et al.*, 2017), anti-inflammatory (de S' a Coutinho *et al.*, 2018), and anti-*T. gondii* (Contreras *et al.*, 2021).

It helps in reducing inflammation along with oxidative stress that contributes to prolonging the lifespan of organisms belonging to different species (Szkudelska *et al.*, 2020).

Antioxidant effect of Resveratrol:

It has a double effect that can increase the activity of antioxidant enzymes and can act as a free radical cleanser (Izzo *et al.*, 2021). Samsamikor *et al.*, 2016 reported that 500 mg/day RV supplementation, significantly increased serum SOD and total antioxidative capacity, and decreased serum MDA concentrations. In addition, it has been shown that RSV can maintain antioxidants levels for biological activities (Zhang *et al.*, 2021).

RSV increase the concentration of some antioxidant enzymes like glutathione peroxidase (GPx), glutathione S-transferase and glutathione reductase (Garcia-Martinez *et al.*, 2021), and can effectively inhibit iNOS production (Zhang *et al.*, 2021).

RSV can attenuate the activation of immune cells and the subsequent synthesis and release of proinflammatory mediators (Meng *et al.*, 2008). Previous studies indicate that RSV treatment modulates cytokine profiles and attenuates inflammatory process caused by *T.gondii* infection (Bottari *et a.*, 2018).

Regarding the antiparasitic activity, RSV possess parasitocidal efficacy against *Leishmania amazonensis* and *Trypanosoma cruzi*. In *Leishmania amazonensis* RSV exhibited both anti-promastigote and anti-amastigote effects, increased the percentage of promastigotes, reduced the mitochondrial potential and decreased the activity of the arginase enzyme in macrophages that lead to elimination of parasites (Ferreira *et al.*, 2014). RSV showed strong anti-parasitic effects against *Trypanosoma cruzi* via promoted metacyclogenesis, reduced epimastigotes growth, blocked differentiation and/or replication of intracellular amastigotes (Campo, 2017).

2-Herbal plants:

➤ *Lepidium sativum* seed extract (LSSE):

Lepidium sativum is a popular herb that commonly known as (Hab el Rashaad or Thufa). It is grown in many regions in Saudi Arabia such as Hijaz, Al-Qaseem and the Eastern province (Gilani *et al.*, 2013).

It is frequently used in Saudi traditional medicine, as well as in many African countries for the treatment of gut disorders like diarrhea among other medicinal uses, while in the Western world its leaves are used in salads (Azaizeh *et al.*, 2006).

Phytochemical studies of *Lepidium sativum* seeds have revealed the presence of tannins, benzyl isothiocyanate, flavonoids, alkaloids, triterpenes and sterols, which are known to have antioxidant, anti-inflammatory, analgesic and anti-parasitic activities (Raish *et al.*, 2016).

Interestingly, *Lepidium sativum* is an antiparasitic with documented efficacy against *Eimeria tenella* (Adamu and Boonkaewwan, 2014), and *Echinococcus granulosus* (Bahrami *et al.*, 2016), in addition, Abuelenain *et al.*, 2021 revealed the anti *Trichinella* activity of *Lepidium sativum*, it resulted in a significant reduction in adult worm numbers and in muscle larvae count.

It was found that *lepidium sativum* seed extract improved leukopenia associated with lymphocytopenia which induced by trypanosome infection (Al-Otaibi *et al.*, 2018). There is significant correlation between LSSE role in decreasing the oxidative stress markers and improvement of hematological parameters (Raish *et al.*, 2016).

Eucalyptus extract:

Eucalyptus is a large genus of Myrtaceae family, represented by 900 species and subspecies. It is native to Australia and can be found all around the world. Native Australians used Eucalyptus leaves for wound healing and treating fungal infections (Gilles *et al.*, 2010).

According to previous studies, *Eucalyptus* has beneficial biological effects such as, anti-microbial, anti-hyperglycemic, anti-oxidant activities and anti-trichomonas activity (Youse *et al.*, 2012).

Eucalyptus extracts contain polyphenols, terpenoid and cineol that had previously displayed remarkable antioxidant activity (El-Moein *et al.*, 2012). It was found that eucalyptol which are the principal compounds of the essential oils of *Eucalyptus* species, exhibit antioxidant activity due to the presence of phenolic compounds (Luís *et al.*, 2017).

Mirzaalizadeh *et al.*, 2018 reported that *Eucalyptus* extract had *in vivo* and *in vitro* anti *Toxoplasma* activities additionally, it showed anti-oxidant effect and higher survival rates.

Olive (*Olea europaea*) extract:

The Olive (*Olea europaea* L.) is a small tree belonging to the family Oleaceae. It is native to tropical and warm temperate regions of the world, and it is one of the oldest known cultivated plants (Boskou, 1996).

Olive leaves are considered as a cheap raw material which can be used as a useful source of high added value products such as phenolic compounds (Briante *et al.*, 2002). Main phenolic compounds in olive leaves extracts are oleuropein, hydroxytyrosol, verbascoside, apigenin-7-glucoside and luteolin-7-glucoside, (Goldsmith *et al.*, 2014)

Olive leaves extract in several studies in animals and humans showed a high antioxidant capacity (Soni *et al.*, 2006) and anti-inflammatory (Khalatbary and Zarrinjoei, 2012)

Maslinic acid (MA) (2R,3-dihydroxyolean-12-en-28-oic acid) is a triterpenoid compound related to oleanolic acid which is found in numerous plants (Juan *et al.*, 2006) especially in considerable amount in fruit and leaves of *Olea europaea* (Lee *et al.*, 2008).

The action of maslinic acid (2R,3-dihydroxyolean-12-en-28-oic acid), a pentacyclic derivative present in the pressed fruits of the olive (*Olea europaea*), against the tachyzoites of *T. gondii* was previously evaluated (De Pablos *et al.*, 2010). The authors observed alterations in gliding motility and ultra-structure in parasites treated with maslinic acid. Maslinic acid worked as other protease inhibitors that inhibit the growth and intracellular replications of *T. gondii* and blocks the entry of parasite into the cell as well. (Jones *et al.*, 2001)

Intersentingly, it was found that olive leaf methanolic extracts has good efficacy and is a promising therapeutic agent against *Cryptosporidium*, diminishing the oocysts shedding, protecting the intestinal epithelial from deleterious effects of *C. parvum* (Abd El-Hamed *et al.*, 2021).

Conclusion

Oxidative stress (OS) plays an essential role in the pathogenesis of common neurodegenerative diseases. We have previously shown that *Toxoplasma gondii* (*T. gondii*) induces high nitric oxide (NO) production, glial activation, and apoptosis that altogether cause severe neuropathology in toxoplasma encephalitis (TE). The objective of this study was to investigate the cytotoxic effect of OS and to identify a correlation between the causes of *T. gondii* induced neuropathology. Expression levels of glutathione reductase (GR), Cu/Zn superoxide dismutase (SOD1), neuron specific enolase (NSE), and 8-hydroxy-2'-deoxyguanosine (8-OHdG) were investigated. Results of the study revealed that the levels of GR ($P < 0.005$) and NSE ($P < 0.001$) expression in the brain tissue markedly increased while SOD1 activity decreased ($P < 0.001$) in the infected group compared to the non-infected group. In addition, intense staining for 8-OHdG ($P < 0.05$) was observed both in the nucleus and the cytoplasm of neurons and glial cells that underwent OS. These results were reasonable to suggest that *T. gondii*-mediated OS might play a pivotal role and a different type of role in the mechanism of neurodegeneration/neuropathology in the process of TE. The results also clearly indicated that increased levels of NO and apoptosis might contribute to OS-related pathogenesis of TE. As a result, OS and expression of NSE might give an idea of the disease progress and may have a critical diagnostic significance for patients with *T. gondii* infection.

References

- Abd El-Hamed, W. F.; Yousef, N. S.; Mazrou, Y. S. A. *et al.*, (2021): Anticryptosporidium Efficacy of *Olea europaea* and *Ficus carica* Leaves Extract in Immunocompromised Mice Associated with Biochemical Characters and Antioxidative System. *Cells*, 10(9): 2419.
- Abd El-Lateef, A.S.; Fayyad, R.A. and Al-Gendy, A.M.M. (2022): Comparative effects of olive leaves extract and silymarin on hepatic redox state in experimentally carbon tetrachloride-induced liver injury in adult male albino rats. *Al-Azhar Med. J. (Medicine)*. 51(2): 1311-1324.
- Abdel Hamed, E.F. ; Mostafa, N.E.; Fawzy, E.M. *et al.*, (2021): The delayed death-causing nature of *Rosmarinus officinalis* leaf extracts and their mixture within experimental chronic toxoplasmosis: Therapeutic and prophylactic implications. *Acta Tropica* (221): 105992.
- Abdul-Ghani, R. (2011): Polymerase chain reaction in the diagnosis of congenital toxoplasmosis: more than two decades of development and evaluation. *Parasitol Res.*, (108): 505–12.
- Abuelenain, G.L.; Fahmy, Z.H.; Elshennawy, A.M. *et al.*, (2021): The potency of *Lepidium sativum* and *Commiphora molmol* extracts on *Trichinella spiralis* stages and host interaction. *Adv. Anim. Vet. Sci.* 9(9): 1376-1382.
- Acquaviva, R. ; Russo, A. ; Campisi, A. *et al.*, (2020): Antioxidant activity and protective effect on DNA cleavage of resveratrol, *J. Food Sci.* 67 (1) (2010): 137–141.
- Adams, L. B.; Hibbs, J. B. Jr.; Taintor, R. R. and Krahenbuhl, J. L. (1990): Micro-biostatic effect of murine-activated macrophages for *Toxoplasma gondii*: Role for synthesis of inorganic nitrogen oxides from L-arginine. *J. Immunol.*, 144(7): 2725–2729.
- Adamu, M. and Boonkaewwan, C. (2014): Effect of *Lepidium sativum* L. (Garden Cress) seed and its extract on experimental *Eimeria tenella* infection in broiler chickens. *Kasetsart J. (Nat. Sci.)* (48): 28–

37.

Bakhraibah, A. (2022): Warm-blooded animal toxoplasmosis and its connection to COVID-19: A review. *Microbial Biosystems*, 7(1): 18-26.

Balagoon, M.J. (2019): Assessment of the Protective Effect of *Lepidium sativum* against Aluminum-Induced Liver and Kidney Effects in Albino Rat. *BioMed Research International*, (2019): 4516730, 9.

Barratt, J. L.; Harkness, J.; Marriott, D.; Ellis, J. T.; and Stark, D. (2010): Importance of non-enteric protozoan infections in immunocompromised people. *Clin. Microbiol. Rev.*, (23): 795– 836.

Bastien, P. (2002): Molecular diagnosis of toxoplasmosis. *Trans. R. Soc. Trop. Med. Hyg.*, 96(Suppl 1): S205 – 15.

Bedard, K. and Krause, K.H. (2007): The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology. *Physiol. Rev.* (87):245–313.

Belluco, S.; Simonato, G.; Mancin, M.; et al., (2018): *Toxoplasma gondii* infection and food consumption: a systematic review and meta-analysis of case-controlled studies. *Crit Rev Food Sci Nutr.* 58(18):3085–3096.

Bennett, R.N.; Mellon, F.A. and Kroon, P.A. (2004): Screening crucifer seeds as sources of specific intact glucosinolates using ion-pair high-performance liquid chromatography negative ion electrospray mass spectrometry. *J Agric Food Chem.* (52):428–38.

Besteiro, S. (2019): The role of host autophagy machinery in controlling *Toxoplasma* infection. *Virulence.* 10 (1):438–447.

Betteridge, D.J. (2000): What is oxidative stress? *Metabolism*, (49): 3–8.

Beutter, E.; Duron, O. and Kelly, M.B. (1963): *J. Lab. Clin. Med.*, 61, 882.

Bionisch, T.M.S. (2001): *Immunological Staining Methods*. 3rd ed. California, USA, Carpinteria.

Black, M. W. and Boothroyd, J.C. (2000): Lytic cycle of *Toxoplasma gondii*, *Microbiol. Mol. Biol. Rev.*, (64): 607-623.

Blume, M. and Seeber, F. (2018): Metabolic interactions between *Toxoplasma gondii* and its host. *F1000Research* (7): 1719.

Borges, M.; Magalhães Silva, T.; Brito, C.; et al., (2019): How does toxoplasmosis affect the maternal-foetal immune interface and pregnancy? *Parasite Immunol.* 41(3): e12606.

Bosch, S.S.; Kronenberger, T.; Meissner, K.A. et al., (2015): Oxidative Stress Control by Apicomplexan Parasites. *BioMed Res. Int.* 1–10.

Boskou, D. (1996): *Olive oil: chemistry and technology*. AOCS Press, Champaign 5.

Cai, G.; Kastelein, R. and Hunter, C.A. (2000): Interleukin-18 (IL-18) Enhances Innate IL-12-Mediated Resistance to *Toxoplasma gondii*. *Infect Immun.* (68): 6932-6938.

Calero-Bernal, R. and Gennari, S.M. (2019): Clinical toxoplasmosis in dogs and cats: an update. *Front Vet Sci.* (6):54.

Campello, Porto, L. and Duarte, E. C. (2012): Association between the risk of congenital toxoplasmosis and the classification of toxoplasmosis in pregnant women and prenatal treatment in Brazil, 1994-2009. *Int. J. Infect. Dis.*, (16):480-486.

Campo, V.A. (2017): Comparative effects of histone deacetylases inhibitors and resveratrol on *Trypanosoma cruzi* replication, differentiation, infectivity and gene expression, *Int. J. Parasitol.* 7 (1):

23–33.

Carne, B.; Bissuel, Ajzenberg, F. D.; Bouyne, R. et al., (2002): Severe acquired toxoplasmosis in immunocompetent adult patients in French Guiana. *Americ. Soci. Mic.*, (7):443-446.

Cattoretti, G.; Becker, M.H.G.; Key, G. et al., (1992): Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. *J Pathol* (168): 357–363.

Cerutti, A.; Blanchard, N. and Besteiro, S. (2020): The bradyzoite: a key developmental stage for the persistence and pathogenesis of toxoplasmosis. *Pathogens*. 9(3).

Cesbron-Delauw, M. F.; Gendrin, C.; Travier, L.; Ruffiot, P. and Mercier, C. (2008): Apicomplexa in mammalian cells: trafficking to the parasitophorous vacuole. *Traffic*, 9(5):657–664.

Chaney, A.L. and Marlbach, E.P. (1962): Modified Reagents for Determination of Urea and Ammonium. *Clinical Chemistry*, (8): 130-132.

Chang, H.R.; Grau, G.E. and Pechere, J.C. (1990): Role of TNF and IL-1 in infections with *Toxoplasma gondii*. *Immunology* 69(1): 33–37.

Charvat, R. and Arrizabalaga, G. (2016): Oxidative stress generated during monensin treatment contributes to altered *Toxoplasma gondii* mitochondrial function. *Sci. Rep.* (6): 22997.

Chatoui, K.; Harhar, H.; El Kamli, T. and Tabyaoui, M. (2020): “Chemical composition and antioxidant capacity of *Lepidium sativum* seeds from four regions of Morocco,” *Evidence-based Complementary and Alternative Medicine*, (2020): 7 pages.

Dahlgren, C. and Karlsson, A. (1999): Respiratory burst in human neutrophils. *J. Immunol. Methods* (232):3–14.

Dalle-Donne, I.; Rossi, R.; Colombo, R.; Giustarini, D. and Milzani, A. (2006): Biomarkers of Oxidative Damage in Human Disease. *Clin. Chem.* (52): 601–623.

Dard, C.; Marty, P.; Brenier-Pinchart, M.P.; et al. (2018): Management of toxoplasmosis in transplant recipients: an update. *Expert Rev Anti Infect Ther.* 16 (6):447–460.

Das, S.; Das, D.K. (2007): Anti-inflammatory responses of resveratrol. *Inflamm Allergy Drug Targets* 6:168–173.

Da-Silva, A.S.; Munhoz, T.D.; Faria, J.L. et al., (2013): Increase nitric oxide and oxidative stress in dogs experimentally infected by *Ehrlichia canis*: effect on the pathogenesis of the disease. *Vet. Microbiol.*, 164(3-4):366-9.

De Pablos, L.M.; dos Santos, M.F.; Montero, E. et al., (2010): Anticoccidial activity of maslinic acid against infection with *Eimeria tenella* in chickens. *Parasitol. Res.* (107): 601–604.

De Pablos, L.M.; Gonzalez, G.; Rodrigues, R. et al., (2010): Action of a pentacyclic triterpenoid, maslinic acid, against *Toxoplasma gondii*. *J. Nat. Prod.* (73):831–834.

de S´a Coutinho, D.; Pacheco, M.T.; Frozza, R.L.; Bernardi, A. (2018): Anti-Inflammatory effects of resveratrol: mechanistic insights. *Int. J. Mol. Sci.* (19): 1812.

Delgado, I.L.S.; Zúquete, S.; Santos, D. et al., (2022): The Apicomplexan Parasite *Toxoplasma gondii*. *Encyclopedia* (2): 189–211.

Demar, M.; Hommel, D.; Djossou, F. et al., (2012): Acute toxoplasmoses in immunocompetent patients hospitalized in an intensive care unit in French Guiana. *Clin. Microbiol. Infect.* 18, E221–E231.

Deng, H.; Devleeschauwer, B.; Liu, M. et al., (2018). Seroprevalence of *Toxoplasma gondii* in pregnant women and livestock in the mainland of China: a systematic review and hierarchical meta-

analysis. *Scientific Reports* 8(1):1-10.

Denkers, E. Y.; Butcher, B. A.; Del Rio, L. and Bennouna, S. (2004): Neutrophils, dendritic cells and *Toxoplasma*. *International journal for parasitology*, 34(3):411–421.

Eissa, M. H.; Abdel Salam, A. M.; Antonious, S. N.; Abdel Gafar, A.R. and Morsy, T. A. (1990): Comparative study of the Sabin-Feldman dye test and the indirect haemagglutination test in serodiagnosis of toxoplasmosis. *J. Egypt Soc. Parasitol.*, (20): 729–35.

Eissa, S. and Shoman, S. (1998) :Markers of invasion and metastasis and markers of tumor proliferation and apoptosis in: Tumors markers. Chapman and Hall, Lippincott- Raven Publisher Inc., London, UK, 131-153.

El Bissati, K.; Zhou, Y.; Paulillo, S.M. et al., (2017): Protein nanovaccine confers robust immunity against *Toxoplasma*. *npj Vaccines* 2(1):1-12.

Elgendy, D.I.; Othman, A.A.; Hasby Saad, M.A.; Soliman, N.A. and Mwafy, S.E. (2020): Resveratrol reduces oxidative damage and inflammation in mice infected with *Trichinella spiralis*. *Journal of Helminthology* 94(e140): 1–10.

El-Moein, N.; Mahmoud, E. and Shalaby, E. (2012): Antioxidant mechanism of active ingredients separated from *Eucalyptus globulus*. *Org. Chem. Curr. Res.* (1).

Elsheikha, H. M.; Aboul-Dahab, M. A. O.; Abdel Maboud A. I. and El- Sherbini, E. T. (2009): Prevalence and risk factors of *Toxoplasma gondii* antibodies in asymptomatic Egyptian blood donors. *Journal of the Egyptian Society of Parasitology*, (39): 351–361.

Engel, G.; Farid, N.; Faul, M.; Richardson, L. and Winneroski, L. (2000): Saltform selection and characterization of LY333531 mesylate monohydrate. *Int. J. Pharm.*, (198):239–247.

Jones, J.L.; Kruszon-Moran, D.; Wilson, M. et al., (2001): *Toxoplasma gondii* infection in the United States: seroprevalence and risk factors. *AmJ Epidemiol.* 154(4):357- 65.

Jones, L. A.; Alexander, J. and Roberts, C. W. (2006): Ocular toxoplasmosis: in the storm of the eye. *Parasite Immunol.*, 28(12):635–642.

Juan, M.E.; Wenzel, U.; Ruiz-Gutierrez, V.; Daniel, H. and Planas, J.M. (2006): Olive fruit extracts inhibit proliferation and induce apoptosis in HT29 human colon cancer cells. *J Nut.* 136(10):2553-7.

Lambert, H.; Hitziger, N.; Dellacasa, I. et al., (2006): Induction of dendritic cell migration upon *Toxoplasma gondii* infection potentiates parasite dissemination. *Cell Microbiol.* 8(10):1611–1623.

Langermans, J.A.; Nibbering, P.H.; Van Vuren-Van der Hulst, M.E.B. and Van Furth, R. (2001): Transforming growth factor- β suppresses interferon γ -induced toxoplasmatatic activity in murine macrophages by inhibition of tumour necrosis factor- α production. *Parasite Immunol.* (23): 169-175.

Lawres, L. A.; Garg, A.; Kumar, V. et al., (2016). Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone. *J. Exp. Med.* (27):1307–1318.

Lebrun, M.; Carruthers, V.B. and Cesbron-Delauw, M.F. (2014): *Toxoplasma* Secretory Proteins and Their Roles in Cell Invasion and Intracellular Survival. In *Toxoplasma Gondii*; Elsevier: Amsterdam, The Netherlands, 389–453.

Lee, I.K.; Kim, D.H.; Lee, S.Y. et al., (2008): Triterpenoic acids of *Prunella vulgaris* var. lilacina and their cytotoxic activities in vitro. *Arch Pharm Res.* 31(12):1578-83.

Lefevre-Pettazzoni, M.; Le Cam, S.; Wallon, M. and Peyron, F. (2006): Delayed maturation of immunoglobulinG avidity: implication for the diagnosis of toxoplasmosis in pregnant women. *Eur. J.*

Clin. Microbiol. Infect. Dis., (25): 687–693.

Levings, M. K.; Bacchetta, R.; Schulz, U. and Roncarolo, M. G. (2002): The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. *International archives of allergy and immunology*, 129(4), 263–276.

Lim, D. C.; Cooke, B. M.; Doerig, C. and Saeij, J. P. (2012): Toxoplasma and Plasmodium protein kinases: roles in invasion and host cell remodeling. *Int. J. Parasitol.*, 42(1):21–32.

Ling, V. J.; Lester, D.; Mortensen, P. B.; Langenberg, P. W. and Postolache, T. T. (2011): Toxoplasma gondii seropositivity and suicide rates in women. *J. Nerv. Ment. Dis.*, (199): 440–444.

Liu, L. D.; Singla, H. and Zhou, H. (2012): Vaccines against Toxoplasma gondii: status, challenges and future directions. *Hum. Vaccin. Immunother.*, (8): 1305-1308.

Liu, Q.; Wang, Z.-D.; Huang, S.-Y. and Zhu, X.-Q. (2015): Diagnosis of toxoplasmosis and typing of Toxoplasma gondii. *Parasites & Vectors*, 8(1).

Lopes-Mori, F.M.; Mitsuka-Bregano, R.; Bittencourt, L.H. et al., (2013): Gestational toxoplasmosis in Parana State, Brazil: prevalence of IgG antibodies and associated risk factors. *Braz. J. Infect. Dis.*, (17): 405-409.

Lopez, A.; Dietz, V. J.; Wilson, M.; Navin, T. R. and Jones, J. L. (2000): In preventing congenital toxoplasmosis: CDC Recommendations Regarding Selected Conditions Affecting Women's Health. *Centers for Disease Control and Prevention MMWR*, (49): 57–75.

Lorestani, A.; Ivey, F.D.; Thirugnanam, S. et al., (2012): Targeted Proteomic Dissection of Toxoplasma Cytoskeleton Sub-Compartments Using MORN1. *Cytoskeleton* (69): 1069–1085.

Lu, F.; Huang, S. and Kasper, L.H. (2003): Interleukin-10 and pathogenesis of murine ocular toxoplasmosis. *Infect Immun.* (71): 7159-7163.

Lu, J.M.; Jin, G.N.; Lu, Y.N. et al., (2021): Resveratrol modulates Toxoplasma gondii infection induced liver injury by intervening in the HMGB1/TLR4/NF-κB signaling pathway. *European Journal of Pharmacology* (910):174497.

Lucas, S.; Bell, J. and Chimelli, L. (2008): —Parasitic and fungal infections, in *Greenfields' Neuropathology*, (1): 1447–1512, Hodder Arnold, London, UK, 8th edition.

Luís, Â.; Duarte, A.P.; Pereira, L. and Domingues, F. (2017): Chemical profiling and evaluation of antioxidant and anti-microbial properties of selected commercial essential oils: a comparative study. *Medicine* (4): 36.

Luna, J.C.; Zamora, A.; Hernández-Arango, N. et al., (2019): Food Safety Assessment and Risk for Toxoplasmosis in School Restaurants in Armenia, Colombia. *Parasitol. Res.* (118): 3449–3457.

Lushchak, V.I. (2014): Free radicals, reactive oxygen species, oxidative stress and its classification. *Chem. Interact.* (224): 164–175.

Lutjen, S.; Soltek, S.; Virna, S.; Deckert, M. and Schluter, D. (2006): Organand disease-stage-specific regulation of Toxoplasma gondii- specific CD8-T-cell responses by CD4 T cells. *Infect. Immun.*, 74(10):5790–5801

Perng, C.; Kearney, A.; Palepu, N.; Smith, B. and Azzarano, L. (2003): Assessment of oral bioavailability enhancing approaches for SB-247083 using flow-through cell dissolution testing as one of the screens. *Int. J. Pharm.*, (250):147–156.

Petersen, E. (2007): Prevention and treatment of congenital toxoplasmosis. *Expert Rev. Anti-Infect. Ther.* 5 (2): 285–293.

Petersen, E.; Borobio, M. V.; Guy, E. et al., (2005): European multicenter study of the LIAISON automated diagnostic system for determination of *Toxoplasma gondii*-specific immunoglobulin G (IgG) and IgM and the IgG avidity index. *J. Clin. Microbiol.*, (43): 1570–1574.

Pfefferkorn, E., and Borotz, S. E. (1994a). Comparison of mutants of *Toxoplasma gondii* selected for resistance to azithromycin, spiramycin, or clindamycin. *Antimicrob. Agents Chemother.* 38, 31–37.

Saab, Y. B. and Mroueh, M. A. (2002): Spiramycin-induced liver injury. *Ann. Pharmacother.*, (36):1972.182.

Saadatnia, G. and Golkar, M. (2012): A review on human toxoplasmosis. *Scandinavian journal of infectious diseases*, 44(11): 805-814.

Sabin, A. and Feldman, H. A. (1948): Dyes as microchemical indicators of a new immunity phenomenon affecting a protozoan parasite (*Toxoplasma*). *Science*, (108):660–3.

Saeij, J.P. and Frickel E.M. (2017): Exposing *Toxoplasma gondii* hiding inside the vacuole: a role for GBPs, autophagy and host cell death. *Curr Opin Microbiol.* (40):72–80.

Saeij, J.P.J.; Boyle, J.P. ; Coller, S.; et al., (2006): Polymorphic secreted kinases are key virulence factors in Toxoplasmosis. *Science*. 314(5806):1780–1783.

Saki, J.; Mohammadpour, N.; Moramezi, F. and Khademvatan, S. (2015): Seroprevalence of *Toxoplasma gondii* in women who have aborted in comparison with the women with normal delivery in Ahvaz, southwest of Iran. *The Scientific World Journal* ,764369.

Sakran, M.; Selim, Y. and Zidan, N. (2014): A new isoflavonoid from seeds of *Lepidium sativum* L. and its protective effect on hepatotoxicity induced by paracetamol in male rats. *Molecules* (19): 15440–15451.

Samsamikor, M.; Daryani, N.E.; Asl, P.R. and Hekmatdoost, A. (2016): Resveratrol supplementation and oxidative/anti-oxidative status in patients with ulcerative colitis: a randomized, double-blind, placebo-controlled pilot study. *Arch. Med. Res.*, 47 (4): 304-309.

Sana, M.; Rashid, M.; Rashid, I. et al., (2022): Immune response against toxoplasmosis some recent updates RH: *Toxoplasma gondii* immune response. *International Journal of Immunopathology and Pharmacology* (36): 1–19.

Sanchez, S.G. and Besteiro, S. (2021): The pathogenicity and virulence of *Toxoplasma gondii*. *Virulence*, Taylor & Francis, 12 (1):3095 - 3114.

Sardinha-Silva, A.; Mendonça-Natividade, F.C.; Pinzan, C.F.; et al. (2019): The lectin-specific activity of *Toxoplasma gondii* microneme proteins 1 and 4 binds Toll-like receptor 2 and 4 N-glycans to regulate innate immune priming. *PLoS Pathog.* 15(6): e1007871.

Scallan, E.; Hoekstra, R. M.; Angulo, F. J. et al., (2011): Foodborne illness acquired in the United States-major pathogens. *Emerg. Infect. Dis.*, (17):7-15.

Scandalios, J.G. (1993): Oxygen Stress and Superoxide Dismutases. *Plant Physiol.* (101):7–12.

Scanga, C.A.; Aliberti, J.; Jankovic, D.; et al., (2002): myD88 is required for resistance to *Toxoplasma gondii* infection and regulates parasite-induced IL-12 production by dendritic cells. *J Immunol.* 168 (12):5997–6001.

Schmidt, D.R.; Hogh, B.; Andersen, O. et al., (2006): Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine. *Eur. J. Pediatr.* (165): 19–25.

Schneider, W.M.; Chevillotte, M.D. and Rice, C.M. (2014): Interferon stimulated genes: a complex

web of host defenses. *Annu Rev Immunol.* (32):513–545.

Seeber, F., and D. Soldati-Favre. (2010): Metabolic pathways in the apicoplast of apicomplexa. *Int Rev Cell Mol Biol.* (281):161–228.

Serranti, D.; Buonsenso, D. and Valentini, P. (2011): Congenital toxoplasmosis treatment. *Eur. Rev. Med. Pharmacol. Sci.*, (15):193–198.

Severance, E. G.; Kannan, G.; Gressitt, K. L. et al., (2012): Anti-gluten immune response following *Toxoplasma gondii* infection in mice. *PLOS ONE.*, 7(11): e50991.

Shammaa, A.M.; Powell, T.G. and Benmerzouga, I. (2021): Adverse outcomes associated with the treatment of *Toxoplasma* infections. *Sci. Rep.* (11): 1035.

Shapiro, K.; Bahia-Oliveira, L.; Dixon, B.; et al. (2019): Environmental transmission of *Toxoplasma gondii*: Oocysts in water, soil and food. *Food Waterborne Parasitol.* (15): e00049.

Shapiro, K.; Kim, M.; Rajal, V.B. et al., (2019): Simultaneous Detection of Four Protozoan Parasites on Leafy Greens Using a Novel Multiplex PCR Assay. *Food Microbiol.* (84): 103252.

Shin, D.W.; Cha, D.Y.; Hua, Q.J.; Cha, G.H. and Lee, Y.H. (2012): Seroprevalence of *Toxoplasma gondii* infection and characteristics of seropositive patients in general hospitals in Daejeon, Korea. *Korean J. Parasitol.*, (47):125-130.

Shonhai, A.; Maier, A.G.; Przyborski, J.M. and Blatch, G.L. (2011): Intracellular protozoan parasites of humans: the role of molecular chaperones in development and pathogenesis. *Protein Pept. Lett.*, (18): 143-157.

Shynlova, O.; Dorogin, A.; Li, Y. and Lye, S. (2014): Inhibition of infection-mediated preterm birth by administration of broad spectrum chemokine inhibitor in mice. *J. Cell. Mol. Med.* 9(18): 1816-1829.

Sibley, L.D. and Boothroyd, J.C. (1992): Virulent strains of *Toxoplasma gondii* comprise a single clonal lineage. *Nature.* 359(6390):82–85.

Silva, D.R.; Sardi, J.D.C.O.; Freires, I.A.; Silva, A.C.B. and Rosalen, P.L. (2019): In silico approaches for screening molecular targets in *Candida albicans*: A proteomic insight into drug discovery and development. *Eur. J. Pharmacol.* (842): 64–69.

Silva, L.A.; Reis-Cunha, J.L.; Bartholomeu, D.C. and Vitor, R.W. (2017): Genetic Polymorphisms and Phenotypic Profiles of Sulfadiazine Resistant and Sensitive *Toxoplasma gondii* Isolates Obtained from Newborns with Congenital Toxoplasmosis in Minas Gerais, Brazil. *PLoS ONE* (12): e0170689.

Singh, C. S. and Paswan, V. K. (2017): The Potential of Garden Cress (*Lepidium sativum* L.) Seeds for Development of Functional Foods. *Advances in Seed Biology.*

Smith, N.C.; Goulart, C.; Hayward, J.A. et al., (2021): Control of human toxoplasmosis. *Int. J. Parasitol.* 51(2– 3):95–121.

Soni, M.G.; Burdock, G.A.; Christian, M.S.; Bitler, C.M. and Crea, R. (2006): Safety assessment of aqueous olive pulp extract as an antioxidant or antimicrobial agent in foods. *Food Chem Toxicol* (44):903–915.

Speer, C.A. and Dubey, J.P. (2005): Ultrastructural differentiation of *Toxoplasma gondii* schizonts (types B to E) and gamonts in the intestines of cats fed bradyzoites. *Int J Parasitol.* 35(2):193–206.

Tait, E. D. and Hunter, C. A. (2009): Advances in understanding immunity to *Toxoplasma gondii*. *Memorias do Instituto Oswaldo Cruz.*, 104(2):201–210.

Tait, E. D.; Jordan, K. A.; Dupont, C. D. et al., (2010): Virulence of *Toxoplasma gondii* is associated

- with distinct dendritic cell responses and reduced numbers of activated CD8⁺ T cells. *J. Immunol.*, 185(3):1502–1512.
- Tamma, P. (2007): Toxoplasmosis. *Pediatr. Rev.*, (28):470-6.
- Tedesco, R. C.; Smith, R. L.; Corte-Real, S. and Calabrese, K. S. (2004): Ocular toxoplasmosis: the role of retinal pigment epithelium migration in infection. *Parasitol. Res.*, 9 (2): 467–472.
- Terman, A.; Kurz, T.; Gustafsson, B. and Brunk, U.T. (2006): Lysosomal labilization. *IUBMB Life* (58): 531–539. *Thammasat Med. J.*, (8): 487–496.
- Thebault, A.; Kooh, P.; Cadavez, V.; et al. (2021): Risk factors for sporadic toxoplasmosis: a systematic review and meta-analysis. *Microb Risk Anal.* (17):100133.
- Tilley, M.; Fichera, M.E.; Jerome, M.E.; et al. (1997): *Toxoplasma gondii* sporozoites form a transient parasitophorous vacuole that is impermeable and contains only a subset of dense-granule proteins. *Infect Immun.* 65(11):4598 – 4605.
- Tomasi, J. P.; Schlit, A. F. and Stadtsbaeder, S. (1986): Rapid double- sandwich enzyme-linked immunosorbent assay for detection of human immunoglobulin-M anti-*Toxoplasma gondii* antibodies. *Journal of clinical microbiology*, 24(5): 849-850.
- Tomavo, S. (2001): The differential expression of multiple iso enzyme forms during stage conversion of *Toxoplasma gondii*: an adaptive developmental strategy. *Int J Parasitol*, 31(10):1023-31.
- Tomavo, S., and Boothroyd, J. C. (1995). Interconnection between organellar functions, development and drug resistance in the protozoan parasite, *Toxoplasma gondii*. *Int. J. Parasitol.* (25): 1293–1299.
- Tonin, A.; Weber, A.; Ribeiro, A. et al., (2015): Serum levels of nitric oxide and protein oxidation in goats seropositive for *Toxoplasma gondii* and *Neospora caninum*. *Comp. Immunol. Microbiol. Infect. Dis.* (41): 55–58.
- Toursel, C.; Dzierszinski, F.; Bernigaud, A.; Mortuaire, M. and Tomavo, S. (2000): Molecular cloning, organellar targeting and developmental expression of mitochondrial chaperone HSP60 in *toxoplasma gondii*. *Mol. Biochem. Parasitol.*, (111):319-332.
- Türko ğlu, S.A.; Yaman, K.; Orallar, H. et al., (2018): Acute toxoplasmosis and antioxidant levels in the liver, kidney and brain of rats. *Ann. Parasitol.* (64): 241–247.
- Tutar, L. and Tutar, Y. (2010): Heat shock proteins; an overview. *Current Pharmaceutical Biotechnology.*, (11): 216-222.
- Udonsom, R.; Buddhironawat, R. and Sukthana, Y. (2010): Is Sabin- Feldman dye test using *T. gondii* tachyzoites from animal inoculation still the best method for detecting *Toxoplasma gondii* antibodies. *Southeast Asian J. Trop. Med. Public Health*, (41):1059–64.
- Vallochi, A. L.; Nakamura, M. V.; Schlesinger, D. et al., (2002): Ocular toxoplasmosis: more than just what meets the eye. *Scandinavian journal of immunology*, 55(4):324–328.
- Van De Crommenacker, J.; Richardson, D.S.; Koltz, A.M.; Hutchings, K. and Komdeur, J. (2011): Parasitic infection and oxidative status are associated and vary with breeding activity in the Seychelles warbler. *Proc. R. Soc. B Biol. Sci.* (279): 1466–1476.
- Van Dyken, S. J. and Locksley, R. M. (2013): —Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease, *Annual Review of Immunology*, 31(1): 317–343.
- Vaz, R.; Thomaz, S.; Sumikawa, E. and Guimaraes, A. (2011): Serological prevalence of *Toxoplasma gondii* antibodies in pregnant women from Southern Brazil. *Parasitol. Res.*, (106):661-665.

Vazifeh, S.; Kananpour, P.; Khalilpour, M.; Eaisalou, S.V. and Hamblin, M.R. (2022): Anti-inflammatory and Immunomodulatory Properties of *Lepidium sativum*. *BioMed Research International*, (2022): 3645038, 12.

Vdoviaková, K.; Vdoviaková, K.; Petrovová, E. et al., (2016): Importance Rat Liver Morphology and Vasculature in Surgical Research. *Medical science monitor: international medical journal of experimental and clinical research*, (22):4716–4728.

Verma, S.K.; Ajzenberg, D.; Rivera-Sanchez, A.; et al. (2015): Genetic characterization of *Toxoplasma gondii* isolates from Portugal, Austria and Israel reveals higher genetic variability within the type II lineage. *Parasitology*. 142(7):948–957.

Viguer, J. M.; Heffernan, J.; Ferrer, P. L.; Peramato, G. and Vicandi, B. (2005): Fine needle aspiration of *Toxoplasma lymphadenitis*: A cytohistologic correlation. *Acta. Cytol.*, (49):139-43.

Vollaire, M. R. Radecki, S. V. and Lappin, M. R. (2005): Seroprevalence of *Toxoplasma gondii* antibodies in clinically ill cats in the United States. *Am. J. Vet. Res.*, (66): 874–877.

Vutova, K.; Peicheva, Z.; Popova, A. et al., (2002): Congenital toxoplasmosis: eye manifestations in infants and children. *Ann. Trop. Paediatr.*, (22):213–8.

Wallon, M.; Cozon, G.; Ecochard, R.; Lewin, P. and Peyron, F. (2001): Serological rebound in congenital toxoplasmosis: long-term follow-up of 133 children. *European journal of pediatrics*, 160(9): 534–540.

Walsh, C. P.; Hammond, S. E.; Zajac, A. M. and Lindsay, D. S. (1999): Survival of *Toxoplasma gondii* tachyzoites in goat's milk: Potential source of human toxoplasmosis. *J. Eukaryot. Microbiol.*, (46): 73S-74S.

Yuan, J.S.; Reed, A.; Chen, F. and Stewart, C.N. (2006): Statistical analysis of real-time PCR data. *BMC Bioinformatics* (7):85.

Yuliawati, I. and Nasronudin, N. (2015): Pathogenesis, diagnostic and management of toxoplasmosis. *Indones J Trop Infect Dis*, 5(4):100.

Yun-Zhong, F.; Sheng, Y. and Guoyao, W.U. (2002): Free radicals, antioxidants, and nutrition. *Nutrition*, (18): 872–879.

Zewczyk-Golec, K.; Pawłowska, M.; Wesołowski, R.; Wróblewski, M. and Mila-Kierzenkowska, C. (2021): Oxidative Stress as a Possible Target in the Treatment of Toxoplasmosis: Perspectives and Ambiguities. *Int. J. Mol. Sci.* (22): 5705.

Zhang, N.Z.; Chen, J.; Wang, M.; Petersen, E. and Zhu, X.Q. (2013): Vaccines against *Toxoplasma gondii*: new developments and perspectives. *Expert Review of Vaccines* 12(11):1287-1299.

Zhang, Z.; Li, Y.; Xie, Q. et al., (2019). The molecular characterization and immunity identification of rhoptry protein 22 of *Toxoplasma gondii* as a DNA vaccine candidate against toxoplasmosis. *Journal of Eukaryotic Microbiology* 66(1):147-157.

Zhang, L.X.; Li, C.X.; Kakar, M.U. et al., (2021): Resveratrol (RV): A pharmacological review and call for further research. *Biomedicine & Pharmacotherapy* (143): 112164.

Zhao, Y.; Ferguson, D. J.; Wilson, D. C. et al., (2009): Virulent *Toxoplasma gondii* evade immunity-related GTPase-mediated parasite vacuole disruption within primed macrophages. *J. Immunol.*, 182(6):3775–3781.

Zhuang, H.; Yao, C.; Zhao, X. et al., (2020): DNA double-strand breaks in the *Toxoplasma gondii*-infected cells by the action of reactive oxygen species. *Parasites Vectors* (13):1–9.